Analgesia (2) | ![]() |
Atrophy (12) | ![]() |
Bleeding (18) | ![]() |
Calculus - lithiasis (23) | ![]() |
Chest pain (2) | ![]() |
Disability (53) | ![]() |
Diverticulitis (1) | ![]() |
Dizziness (10) | ![]() |
Dystrophy (1) | ![]() |
Edema (6) | ![]() |
Fever (73) | ![]() |
Fibrosis (13) | ![]() |
Illness (360) | ![]() |
Malignancy (10) | ![]() |
Preeclampsia (3) | ![]() |
Sickness (11) | ![]() |
Splenomegaly (1) | ![]() |
Ulcer (29) | ![]() |
and hematologic malignancies wrote first author Mazyar Shadman M d. M p h. a senior fellow in the Clinical Research Division at Fred Hutchinson Cancer Research center.
Of the 79300 VITAL participants who filled out the questionnaires more than 66000 individuals were selected after eliminating those who had a prior history of malignancies other than non-melanoma skin cancers and missing information on baseline cancer history.
Participants were followed for a median of eight years until they withdrew from the study moved away had a cancer diagnosis other than hematologic malignancy
Incidence of hematologic malignancies and other cancers was identified via the Surveillance Epidemiology and End Results (SEER) cancer registry of western Washington.
Of the participants 681 developed a hematologic malignancy during the follow-up period. These participants were more likely to be male to have two
A history of allergies to airborne antigens was associated with a higher risk of hematologic malignancies.
and hematologic malignancies and found that a history of allergies to plants grass and trees was associated significantly with mature B-cell neoplasms one of four major categories of lymphoma.
It is tempting to speculate that the additional effect of allergy may reach statistical significance in women because of their lower baseline risk for the development of hematologic malignancies compared to men the authors wrote.
and progression to malignancy the authors write. Story Source: The above story is provided based on materials by JAMA-Journal of the American Medical Association.
STAT3 is the primary marker that is used today to ascertain malignancy tumor aggression and metastasis in ovarian cancer.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011